NASDAQ · Biotechnology

ATOS (ATOS) Stock

$2.36 -2.48% NASDAQ: ATOS Healthcare

Valuation

MetricValue
Price$2.36
Market Cap$23.54M
P/E Ratio-1.23
P/B Ratio1.10
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$19.35
52-Week Low$1.74
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-89.74%
ROA-72.92%
ROCE-92.50%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio5.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-21.0M$-28.0M$-31.0M$-28.0M$-37.0M
Net Profit$-21.0M$-27.0M$-30.0M$-26.0M$-35.0M
EPS$-2.70$-3.15$-3.60$-3.00$-4.04
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$141.0M$124.0M$96.0M$76.0M$48.0M
Total Liabilities$3.0M$6.0M$5.0M$5.0M$8.0M
Cash$136.0M$111.0M$88.0M$71.0M$41.0M
Borrowings$0$0$0$0$0

Latest News

ATOS: Raises up to $16.5 Million in Registered Direct Offering Zacks Small Cap Research · Jul 1, 2026 Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR Newswire · Jun 12, 2026 Top Midday Decliners MT Newswires · Jun 11, 2026 Atossa Therapeutics Launches $16.5 Million Registered Direct Offering MT Newswires · Jun 11, 2026 Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR Newswire · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-16.0M$-21.0M$-21.0M$-21.0M$-30.0M
Investing Cash Flow$0$-5.0M$0$0$0
Financing Cash Flow$44.0M$0$-1.0M$0$0
Net Cash Flow$97.0M$-25.0M$-22.0M$-17.0M$-30.0M
Free Cash Flow$-16.0M$-21.0M$-21.0M$-21.0M$-30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-78.03%
Quick Ratio4.92
Interest Coverage—
Return 1Y-82.12%
Return 3Y-86.88%
Return 5Y-96.39%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CGTX $0.89 +0.21% -3.94 $79.79M 0.00%
CLNNClene Inc. $5.29 -1.86% -1.66 $54.53M 0.00%
COYA $4.00 -6.21% -2.62 $72.84M 0.00%
GLSI $14.36 +0.84% -21.98 $210.78M 0.00%
IMMX $8.55 +4.65% -9.96 $465.14M 0.00%

About ATOS

ATOS is led by CEO Steven C. Quay, employs 15 people, headquartered in US, publicly traded since 2012.

ATOS stock trades at $2.36 with a market capitalization of $23.54M. The stock is valued at a price-to-earnings (P/E) ratio of -1.23, price-to-book of 1.10, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.74 and $19.35, and currently trades 87.8% below its 52-week high.

On profitability, ATOS generates a return on equity (ROE) of -89.74%, return on capital employed of -92.50%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides